<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND/AIMS: Loss of Smad4 function is associated with the acquisition of advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> phenotypes </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated the role of Smad4 as a prognostic marker after curative therapy </plain></SENT>
<SENT sid="2" pm="."><plain>METHODOLOGY: Four hundred and twenty nine consecutive <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> were analyzed by tissue microarray-based immunohistochemical assay </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Smad4 protein was expressed in 61.5% (24/39), 53.1% (77/145), 41.3% (78/189) and 34.8% (16/46) of stage I, II, III and IV <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>Lymphovascular invasion and lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> were strongly correlated with the loss of Smad4 expression (p&lt;0.0001 and p=0.002, respectively) </plain></SENT>
<SENT sid="5" pm="."><plain>Disease-free survival did not differ between Smad4-positive and Smad4-negative <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>In stage III disease, time to recurrence after curative therapy was shorter in the Smad4-negative than in the Smad4- positive <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> (20.1±15.1 vs. 34.6 ± 34.1 months, p=0.035) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Smad4 protein is of no value in predicting recurrence after curative therapy in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, but it may be helpful in identifying a subset of patients with early recurrence after curative therapy </plain></SENT>
</text></document>